Supernus, Inc. SUPN
29.45 USD +0.70 (+2.43%)
At closeNov 11, 2026, 4:00 PM EST
29.45 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
28.71 Day range 29.66
25.92 52-week range 42.81
- YTD
- -17.92%
- 1 year
- -5.21%
News
globenewswire.com Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous…
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.
benzinga.com B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 B of A Securities analyst Chi Fong initiates coverage on Supernus (NASDAQ:SUPN) with a Buy rating and announces Price Target of $47.
defenseworld.net Head-To-Head Review: Supernus Pharmaceuticals (NASDAQ:SUPN) and Chugai Pharmaceutical (OTCMKTS:CHGCY) Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast…
benzinga.com Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target Piper Sandler analyst David Amsellem reinstates Supernus (NASDAQ:SUPN) with a Overweight and announces $47 price target.
247wallst.com Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades…
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.
benzinga.com Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87 Cantor Fitzgerald analyst Kristen Kluska maintains Supernus (NASDAQ:SUPN) with a Overweight and raises the price target from $67 to $87.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
fool.com Why Indivior Pharmaceuticals Stock Topped the Market Today The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.
globenewswire.com Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior…
benzinga.com Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.- benzinga.com Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses…
globenewswire.com Supernus Announces Third Quarter 2026 Financial Results ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of…
globenewswire.com Indivior Reports Third Quarter 2026 Financial Results Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record…
benzinga.com MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20261022-1485639/1485639_msgs-supn-6.pdf- benzinga.com Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
defenseworld.net Indivior (INDV) Projected to Announce Earnings on Thursday Indivior (NASDAQ: INDV - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Indivior to post earnings of $1.06 per share…
globenewswire.com Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
globenewswire.com Indivior to Report Third Quarter 2026 Financial Results RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29,…
defenseworld.net Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $45.17 Shares of Indivior PLC (NASDAQ: INDV - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are covering the stock, Marketbeat.com reports. One research analyst has…
defenseworld.net Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV) Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
businesswire.com Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
businesswire.com Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
globenewswire.com Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special…
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
defenseworld.net HighTower Advisors LLC Makes New $3.41 Million Investment in Indivior PLC $INDV HighTower Advisors LLC acquired a new stake in Indivior PLC (NASDAQ: INDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…
gurufocus.com INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. U
businesswire.com INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing…
benzinga.com Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
benzinga.com Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
benzinga.com UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.42 by 26.19 percent. This is a 32.5 percent increase over…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…- benzinga.com Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock…
benzinga.com Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67 Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.
benzinga.com Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript 
benzinga.com Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 million to $840.000 million-$870.000 million vs $862.242 million estimate.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For February 24, 2026
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
benzinga.com Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Earnings Scheduled For August 5, 2025
benzinga.com Earnings Scheduled For May 6, 2025 - benzinga.com Earnings Scheduled For February 25, 2025